转移因子口服液联合孟鲁司特钠对肺炎支原体肺炎患儿免疫功能及炎性因子的影响  

Effects of transfer factor oral solution combined with Montelukast sodium on immune function and inflammatory factors in children with Mycoplasma pneumoniae pneumonia

作　　者：安婷 AN Ting(Department of Medicinal Materials of Xinbin Manchu Autonomous County People’s Hospital,Fushun 113200 Liaoning,China)

机构地区：[1]新宾满族自治县人民医院药材科,辽宁抚顺113200

出　　处：《中国民康医学》2021年第1期129-131,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察转移因子口服液联合孟鲁司特钠对肺炎支原体肺炎患儿免疫功能及炎性因子的影响。方法:选取81例肺炎支原体肺炎患儿作为研究对象,按随机数字表法将其分为对照组40例与观察组41例。两组均接受常规对症治疗,对照组予以孟鲁司特钠口服治疗,观察组在对照组基础上联合转移因子口服液治疗,比较两组临床疗效、免疫功能指标水平、炎性因子水平和不良反应发生率。结果:观察组治疗总有效率为92.68%(38/41),明显高于对照组的75.00%(30/40),差异有统计学意义(P<0.05);治疗后观察组免疫蛋白球G、免疫蛋白球A和免疫蛋白球M水平低于对照组,差异均有统计学意义(P<0.05);观察组白细胞介素-2、白细胞介素-18和白细胞介素-13水平低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:转移因子口服液联合孟鲁司特钠可提高肺炎支原体肺炎患儿的治疗总有效率,以及降低免疫功能指标水平和炎性因子水平的效果优于单纯孟鲁司特钠口服治疗效果。Objective:To explore effects of transfer factor oral solution combined with Montelukast sodium on immune function and inflammatory factors in children with Mycoplasma pneumoniae pneumonia.Methods:81 children with Mycoplasma pneumoniae pneumonia were selected as the research objects,and were divided into control group(40 cases)and observation group(41 cases)according to the random number table method.Both groups received routine symptomatic treatment.Besides,the control group was treated with Montelukast sodium orally,while the observation group was treated with transfer factor oral solution on the basis of that of the control group.The clinical efficacy,immune function index levels,inflammatory factor levels and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 92.68%(38/41),which was significantly higher than the control group of 75.00%(30/40),and the difference was statistically significant(P<0.05).After the treatment,the levels of immune protein globulin G,immune protein globulin A and immune protein globulin M in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of interleukin-2,interleukin-18 and interleukin-13 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusions:Transfer factor oral solution combined with Montelukast sodium in the treatment of the children with Mycoplasma pneumoniae pneumonia can increase the total effective rate of treatment,and reduce the levels of immune function indicators and inflammatory factors.Moreover,it is superior to single Montelukast sodium.

关 键 词：肺炎支原体肺炎 转移因子口服液 孟鲁司特钠 免疫功能 炎性因子 

分 类 号：R725.6[医药卫生—儿科]